Analyst consensus rating
Aurinia Pharmaceuticals Analyst Rating: Strong Buy
AUPH is rated Strong Buy by 7 analysts with a $17.86 target. As of 2026-08-26.
Direct answer
Aurinia Pharmaceuticals's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.86.
Forecast evidence checked August 26, 2026.
Get free Aurinia Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $16.52
- Average price target
- $17.86
- High price target
- $21.00
- Low price target
- $16.00
- Low target gap
- -3.1%
- Target upside
- +8.1%
- High target gap
- +27.1%
- Target range width
- 30.3%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $17.86.
How far are Aurinia Pharmaceuticals's low and high targets from the recorded price?
The low target implies -3.1%, while the high target implies +27.1%.
How many analysts are included in Aurinia Pharmaceuticals's consensus?
The verified consensus includes 7 analysts.
How is Aurinia Pharmaceuticals's target upside or downside calculated?
The average target of $17.86 is divided by the recorded price of $16.52, then one is subtracted to produce +8.1%. This does not guarantee a future return.
When was Aurinia Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.